CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more
CG Oncology, Inc. Common stock (CGON) - Net Assets
Latest net assets as of December 2025: $752.60 Million USD
Based on the latest financial reports, CG Oncology, Inc. Common stock (CGON) has net assets worth $752.60 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($791.59 Million) and total liabilities ($38.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $752.60 Million |
| % of Total Assets | 95.07% |
| Annual Growth Rate | 107.94% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 119.43 |
CG Oncology, Inc. Common stock - Net Assets Trend (2021–2025)
This chart illustrates how CG Oncology, Inc. Common stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CG Oncology, Inc. Common stock (2021–2025)
The table below shows the annual net assets of CG Oncology, Inc. Common stock from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $752.60 Million | +2.62% |
| 2024-12-31 | $733.38 Million | +296.87% |
| 2023-12-31 | $184.79 Million | +47.62% |
| 2022-12-31 | $125.18 Million | +210.98% |
| 2021-12-31 | $40.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CG Oncology, Inc. Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33308400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.00% |
| Other Components | $1.13 Billion | 150.35% |
| Total Equity | $752.60 Million | 100.00% |
CG Oncology, Inc. Common stock Competitors by Market Cap
The table below lists competitors of CG Oncology, Inc. Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
$4.27 Billion |
|
Sigma Foods, S.A.B. de C.V.
MX:SIGMAFA
|
$4.27 Billion |
|
Dillard's, Inc.
NYSE:DDS
|
$4.27 Billion |
|
Ho Chi Minh City Development Joint Stock Commercial Bank
VN:HDB
|
$4.29 Billion |
|
Inari Medical Inc
NASDAQ:NARI
|
$4.27 Billion |
|
Ono Pharmaceutical Co. Ltd
PINK:OPHLF
|
$4.26 Billion |
|
SWIGGY LIMITED
NSE:SWIGGY
|
$4.26 Billion |
|
BB Seguridade Participacoes SA
PINK:BBSEY
|
$4.26 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CG Oncology, Inc. Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 733,377,000 to 752,602,000, a change of 19,225,000 (2.6%).
- Net loss of 160,995,000 reduced equity.
- New share issuances of 147,450,000 increased equity.
- Other factors increased equity by 32,770,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-161.00 Million | -21.39% |
| Share Issuances | $147.45 Million | +19.59% |
| Other Changes | $32.77 Million | +4.35% |
| Total Change | $- | 2.62% |
Book Value vs Market Value Analysis
This analysis compares CG Oncology, Inc. Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 106.70x to 6.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.60 | $64.45 | x |
| 2022-12-31 | $1.88 | $64.45 | x |
| 2023-12-31 | $2.77 | $64.45 | x |
| 2024-12-31 | $11.73 | $64.45 | x |
| 2025-12-31 | $9.74 | $64.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CG Oncology, Inc. Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3985.02%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.05x
- Recent ROE (-21.39%) is above the historical average (-23.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -31.90% | -123.95% | 0.18x | 1.46x | $-16.86 Million |
| 2022 | -28.31% | -18556.54% | 0.00x | 1.18x | $-47.96 Million |
| 2023 | -26.30% | -23826.96% | 0.00x | 1.08x | $-67.09 Million |
| 2024 | -12.00% | -7729.50% | 0.00x | 1.03x | $-161.38 Million |
| 2025 | -21.39% | -3985.02% | 0.01x | 1.05x | $-236.26 Million |
Industry Comparison
This section compares CG Oncology, Inc. Common stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CG Oncology, Inc. Common stock (CGON) | $752.60 Million | -31.90% | 0.05x | $4.27 Billion |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |